Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Saturday, November 17, 2018 · 468,609,656 Articles · 3+ Million Readers

Intellia Therapeutics to Present at November Healthcare Investor Conferences

/EIN News/ -- CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare conferences in November:

Tuesday, November 13, 2018
Credit Suisse Healthcare Conference
Location: Scottsdale, Arizona
Time: 2:50pm MT (4:50pm ET)

Thursday, November 15, 2018
Jefferies London Healthcare Conference
Location: London, United Kingdom
Time: 12:40pm GMT (7:40am ET)

Thursday, November 29, 2018
Barclays Gene Editing and Gene Therapy Summit
Location: New York, NY
Time: 3:00pm ET

A live webcast of Intellia’s presentations at the Credit Suisse Healthcare Conference and Jefferies London Healthcare Conference will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each conference.

About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

Investor Contact:                                         
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com

Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com

Intellia.jpg

Powered by EIN News